Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Paolo Caimi, MD, discusses the rationale behind evaluating LMY-920, a novel BAFF CAR T-cell therapy, in relapsed/refractory non-Hodgkin lymphoma.

Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL

David H. Aggen, MD, PhD, details the evolving landscape of treating patients with urothelial carcinoma.

Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment

Jennifer Scalici, MD, discusses data for IMNN-001plus chemotherapy in advanced ovarian cancer.

Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer

Steven H. Lin, MD, PhD, discusses the safety of NKTR-255 in enhancing immune recovery post-chemoradiation in locally advanced NSCLC.

Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

 as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: 

Articles

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for 

as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Zorifertinib has received NMPA approval in the first line for EGFR-mutant advanced or metastatic non–small cell lung cancer displaying CNS metastases.

Zorifertinib Receives NMPA Approval for EGFR+ NSCLC With CNS Metastases

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​ 

The FDA has approved revised drug labeling for fludarabine phosphate under Project Renewal.

FDA Approves New Drug Labeling for Fludarabine Phosphate in CLL

Parth A. Desai, MBBS, MD, was first author on a study that detailed significant findings in small cell lung cancer.

Fox Chase Cancer Center Researcher Find New Treatment Targets in Microenvironment of Small Cell Lung Cancer

Serious questions must be asked about the current state of interventional trials in the oncology sphere and how to improve their future value.

Cancer Clinical Trials: A Relevant Need to Clearly Define the Value to Individual Patients

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Evolving Treatment in Newly Diagnosed Multiple Myeloma Patients

Overview of PERSEUS, IsKia, and GMMG-HD7

Please provide a brief overview of the following trials:

Videos

Elizabeth O’Donnell, MD, discusses how recent clinical trial findings are reshaping frontline treatment strategies for transplant-ineligible patients with newly diagnosed multiple myeloma, emphasizing the importance of patient-specific factors in therapy selection.

Furthermore, Douglas Sborov, MD, discusses how recent advancements in clinical trials and treatment strategies are reshaping the management of newly diagnosed multiple myeloma patients who are eligible for transplant.

Elizabeth O’Donnell, MD, discusses the key considerations when choosing frontline therapy for transplant-ineligible patients with newly diagnosed multiple myeloma and how factors such as frailty, age, and performance status influence the decision-making process.

Key Considerations and Patient Factors in Frontline Therapy Selection for Transplant-Ineligible NDMM Patients

Elizabeth O’Donnell, MD, provides a brief overview of key findings from the MAIA, IMROZ, BENEFIT, and CEPHEUS trials, highlighting significant developments in the treatment of transplant-ineligible patients with newly diagnosed multiple myeloma.

Brief Overview of MAIA, IMROZ, BENEFIT, and CEPHEUS Clinical Trials

Elizabeth O’Donnell, MD, comments on how the aforementioned trials have influenced the treatment landscape for transplant-ineligible patients with newly diagnosed multiple myeloma and discusses situations in which she favors triplet therapy over quadruplet therapy for these patients.

Impact of Clinical Trials on the Treatment Landscape for TIE NDMM and Decision-Making Between Triplet vs Quadruplet Therapy

Elizabeth O’Donnell, MD, comments on specific patient subgroups, such as frail or high-risk individuals, who benefit most from particular regimens. She discusses adverse events observed in combination therapies for transplant-ineligible patients with newly diagnosed multiple myeloma and shares her approaches to managing these adverse effects in clinical practice.

Optimizing Regimens and Managing Adverse Events in TIE NDMM

Elizabeth O’Donnell, MD, comments on the most significant advancements for frontline therapy in transplant-ineligible patients with newly diagnosed multiple myeloma. She also provides key takeaways from the latest clinical trial data, discussing how she anticipates these findings will impact her day-to-day clinical practice.

Looking Ahead and Key Takeaways

Douglas Sborov, MD, discusses how key factors, such as patient eligibility for  ASCT, decision-making processes for patients with transplant-eligible NDMM, and the influence of depth of response, including MRD negativity, shape frontline therapy strategies.

Current Treatment Landscape of Newly Diagnosed Multiple Myeloma Patients

Douglas Sborov, MD, discusses a brief overview of key clinical trials, including PERSEUS, IsKia, and GMMG-HD7, highlighting their implications for the treatment of patients with NDMM.

Douglas Sborov, MD, discusses the most reported adverse events in transplant-eligible patients undergoing triplet or quadruplet therapy, as well as significant advancements on the horizon for frontline treatment in NDMM and key takeaways from recent clinical trial data that may impact clinical practice.

Overview of PERSEUS, IsKia, and GMMG-HD7

EP: 1.Key Considerations and Patient Factors in Frontline Therapy Selection for Transplant-Ineligible NDMM Patients

EP: 2.Brief Overview of MAIA, IMROZ, BENEFIT, and CEPHEUS Clinical Trials

EP: 3.Impact of Clinical Trials on the Treatment Landscape for TIE NDMM and Decision-Making Between Triplet vs Quadruplet Therapy

EP: 4.Optimizing Regimens and Managing Adverse Events in TIE NDMM

EP: 5.Looking Ahead and Key Takeaways

EP: 6.Current Treatment Landscape of Newly Diagnosed Multiple Myeloma Patients

EP: 7.Overview of PERSEUS, IsKia, and GMMG-HD7

EP: 8.Clinical Factors for Transplant Eligibility and Treatment Strategy in NDMM

Latest Conference Coverage